Clinical and germline risk factors for multiple treatment-related toxicities in pediatric acute lymphoblastic leukemia [0.03%]
儿科急性淋巴细胞白血病多重治疗相关毒性的临床和胚系危险因素分析
Marion K Mateos,Chelsea Mayoh,Patricia Sullivan et al.
Marion K Mateos et al.
Not available.
Patient-centered care strategies for Jehovah's Witnesses with acute leukemia and high-grade myeloid neoplasms [0.03%]
急性白血病和高级别骨髓瘤的耶和华见证人的以患者为中心的护理策略
Jabra Zarka,Aref Al-Kali,Hassan B Alkhateeb et al.
Jabra Zarka et al.
Not available.
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R [0.03%]
DA-EPOCH-R作为一线治疗后复发或难治性原发纵隔B细胞淋巴瘤患者的结局分析
Brian Hess,Alison Moskowitz,James A Davis et al.
Brian Hess et al.
Introduction: Most patients diagnosed with primary mediastinal B-cell lymphoma (PMBCL) achieve cure following standard of care therapy with frontline DA-EPOCH-R. However, treatment strategies following relapse after DA-EP...
Children with chronic phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML [0.03%]
慢性期儿童慢性髓性白血病的特征和预后：国际儿童慢性髓性白血病注册登记数据
Frédéric Millot,Joe De Keizer,Markus Metzler et al.
Frédéric Millot et al.
Five hundred and thirty-five patients (median age 12.2 years, range: 8 months - 18 years; N=303 males, N=232 females) diagnosed with chronic myeloid leukaemia (CML) in chronic phase were registered in the International Registry of Childhood...
Age-specific mutation profiles and their prognostic implications in pediatric KMT2A-rearranged acute myeloid leukemia [0.03%]
儿科KMT2A重排急性髓系白血病的年龄特异性突变谱及其预后意义
Kota Shoji,Kenichi Yoshida,Shinju Iyoda et al.
Kota Shoji et al.
Driver mutations in KMT2A-rearranged (KMT2A-r) have been identified in acute myeloid leukemia (AML); however, age-related differences in their frequency and prognostic factors remain unclear. In this study, we report age-specific mutation p...
The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study [0.03%]
达拉莫单抗诱导治疗对新诊断多发性骨髓瘤患者造血干细胞动员、采集及植入的影响：DILEMMA研究的前瞻性结果分析
Caterina Giovanna Valentini,Claudio Pellegrino,Patrizia Chiusolo et al.
Caterina Giovanna Valentini et al.
Not available.
Clinical and genomic features of macrofocal multiple myeloma: a distinct profile [0.03%]
大片型多发性骨髓瘤的临床和基因组特征：一种不同的谱系
Jin Liu,Jianling Fan,Xinyi Zhou et al.
Jin Liu et al.
Not available.
Clinical activity of venetoclax and azacitidine in children with de novo or secondary multiple relapsed/refractory acute myeloid leukemia: a real-world experience [0.03%]
维奈托克和阿扎胞苷治疗儿童复发/难治急性髓系白血病的临床疗效：真实世界经验
Agathe Arcourt,Uri Ilan,Laura Murillo et al.
Agathe Arcourt et al.
Acute myeloid leukemia (AML) remains a major therapeutic challenge, particularly in relapsed or refractory patients, where prognosis is poor. The combination of venetoclax and azacitidine has demonstrated significant efficacy in adults, yet...
Lenalidomide-associated reversible TP53-mutated clonal hematopoiesis in plasma cell neoplasms [0.03%]
来那度胺所致可逆性TP53突变型克隆型血液病在浆细胞瘤中的出现
Christian B Gocke,Mareike Peters,Christopher D Gocke et al.
Christian B Gocke et al.
Not available.
Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation [0.03%]
奥雷巴替尼治疗加速期慢性髓性白血病的疗效和安全性评估研究
Mengyao Yuan,Li Zhou,Weiming Li et al.
Mengyao Yuan et al.
We studied 130 consecutive subjects who presented with (n = 29) or transformed to (n = 101) accelerated phase chronic myeloid leukemia (CML) and who received olverembatinib. 62 were in 2nd chronic phase. All failed ≥ 1 tyrosine kinase-inhi...